|
|
|
Volumn 55, Issue 1425, 2013, Pages 75-76
|
|
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CAPECITABINE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
KETOCONAZOLE;
LAPATINIB;
TAXANE DERIVATIVE;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
ANTINEOPLASTIC AGENT;
ERBB2 PROTEIN, HUMAN;
MAYTANSINE;
MONOCLONAL ANTIBODY;
APOPTOSIS;
BREAST METASTASIS;
CANCER SURVIVAL;
CELL CYCLE ARREST;
CONSTIPATION;
DISEASE COURSE;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG WITHDRAWAL;
FATIGUE;
HEADACHE;
HEART LEFT VENTRICLE EJECTION FRACTION;
HUMAN;
LETTER;
LIVER TOXICITY;
MUSCULOSKELETAL PAIN;
NAUSEA;
OVERALL SURVIVAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RECOMMENDED DRUG DOSE;
SIDE EFFECT;
THROMBOCYTOPENIA;
ANALOGS AND DERIVATIVES;
ANTAGONISTS AND INHIBITORS;
BREAST NEOPLASMS;
DISEASE FREE SURVIVAL;
DRUG ADMINISTRATION;
DRUG INTERACTION;
ECONOMICS;
ENZYMOLOGY;
FEMALE;
INTRAVENOUS DRUG ADMINISTRATION;
METABOLISM;
MORTALITY;
SECONDARY;
TIME FACTOR;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BREAST NEOPLASMS;
DRUG ADMINISTRATION SCHEDULE;
DRUG INTERACTIONS;
FEMALE;
HUMANS;
INFUSIONS, INTRAVENOUS;
MAYTANSINE;
NEOPLASM METASTASIS;
RECEPTOR, ERBB-2;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 84884134374
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (4)
|
|
References (5)
|
